(HealthDay News) – A genetically-engineered tomato containing apoA-I mimetic peptide, and bile salt hydrolase (BSH)-active Lactobacillus reuteri (L. reuteri) NCIMB 30242 capsules may be promising for favorably affecting cholesterol levels.
Arnab Chattopadhyay, PhD, from the University of California Los Angeles, and colleagues generated transgenic tomato plants carrying an empty vector or one expressing the apoA-I mimetic peptide, L-6F. Ripened tomatoes were harvested, lyophilized, ground, added to a western diet, and fed to LDLR null mice. The researchers found that feeding the mice with L-6F-containing tomatoes for two weeks, compared with control tomatoes, correlated with a significant reduction in plasma serum amyloid A levels and increases in plasma paraoxonase activity.
Mitchell L. Jones, MD, PhD, from McGill University in Montreal, and colleagues examined the effect of probiotic bacterial strains on cholesteryl esters. During a nine-week intervention period, 127 individuals were randomly allocated to consume BSH-active L. reuteri NCIMB 30242 capsules or placebo capsules. The researchers found that there was a significant 6.3% reduction in total cholesteryl esters and an 8.8% reduction in cholesteryl ester saturated fatty acids for the group allocated to L. reuteri NCIMB 30242 capsules. The reductions in cholesteryl esters and cholesteryl ester saturated fatty acids were linked to decreases in apoB-100 and low-density lipoprotein cholesterol.
“L. reuteri NCIMB 30242 capsules were shown to lower cholesteryl ester saturated fatty acids over a nine-week intervention period,” Jones and colleagues write.
Several authors from the first study disclosed financial ties to Bruin Pharma. Several authors from the second study disclosed financial ties to Micropharma, which funded the study and owns intellectual property rights for the formulation.